Business Context and Reporting Period
This Form 8-K is filed by Big Rock Partners Acquisition Corp. (not NRX Pharmaceuticals, Inc., as indicated in the metadata) on November 28, 2017. The report details the completion of the company's Initial Public Offering (IPO) and the subsequent exercise of the underwriters' over-allotment option. The company is a Delaware corporation and an emerging growth company.
Key Financial Metrics
- Total Gross Proceeds: $71,725,000 (comprising $60,000,000 from the initial IPO, $9,000,000 from the over-allotment, $2,500,000 from the initial private placement, and $225,000 from the over-allotment private placement).
- Trust Account Deposit: $69,000,000 of net proceeds were deposited into a trust account for public stockholders.
- Units Sold: 6,900,000 Units in total (6,000,000 initial + 900,000 over-allotment).
- Offering Price: $10.00 per Unit.
- Private Placement: 272,500 Placement Units sold at $10.00 each.
- Revenue/Profit/Cash Flow: The filing text does not provide operating revenue, profit, or cash flow metrics as the company is a special purpose acquisition company (SPAC) in its formation stage.
Material Changes
The primary material change is the full exercise of the underwriters' over-allotment option on November 28, 2017, closing on November 29, 2017. This resulted in the sale of an additional 900,000 Units and 22,500 Placement Units, increasing total capital raised by $9,225,000 compared to the initial IPO closing on November 22, 2017.
Outlook and Management Commentary
- Separate Trading: Commencing December 1, 2017, holders may elect to separately trade the underlying securities (Common Stock, Warrants, and Rights).
- Trading Symbols: Units will trade as "BRPAU"; separated Common Stock as "BRPA"; Warrants as "BRPAW"; and Rights as "BRPAR".
- Financial Statements: An audited balance sheet as of November 22, 2017 (excluding over-allotment proceeds) and an unaudited pro forma balance sheet (including over-allotment proceeds) are included as exhibits.
- Risks/Contingencies: The filing notes that securities in the private placement were issued under Section 4(a)(2) and Regulation D exemptions. No specific operational risks are detailed in this specific excerpt beyond standard SPAC formation disclosures.
Investor Verification Checklist
- Verify the final amount held in the trust account ($69,000,000) against the pro forma balance sheet (Exhibit 99.2).
- Confirm the ticker symbols for separated securities (BRPA, BRPAW, BRPAR) on the NASDAQ Capital Market.
- Review the terms of the Rights and Warrants included in the Units to understand dilution potential upon a future business combination.
- Check the press release (Exhibit 99.3) for any additional details on the separation process for shareholders.